Clinical studies and experimental evidence suggest that PXR activation by vitamin K2 can potentially alleviate the symptoms of IBD by mitigating inflammation, maintaining intestinal homeostasis, and promoting the detoxification of harmful compounds [85,86,87]. This evidence concerns the gene NR1I2 and irritable bowel syndrome.